Related Experiment Video
Updated: Aug 26, 2026
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
Published on: February 28, 2019
Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity
Balaji M Rao1, Andrew T Girvin, Thomas Ciardelli
1Department of Chemical Engineering and Biological Engineering Division, Massachusetts Institute of Technology, MIT 66-552, Cambridge, MA 02139, USA.
Abstract:
Stimulation of T-cells by IL-2 has been exploited for treatment of metastatic renal carcinoma and melanoma. However, a narrow therapeutic window delimited by negligible stimulation of T-cells at low picomolar concentrations and undesirable stimulation of NK cells at nanomolar concentrations hampers IL-2-based therapies. We hypothesized that increasing the affinity of IL-2 for IL-2Ralpha may create a class of IL-2 mutants with increased biological potency as compared with wild-type IL-2. Towards this end, we have screened libraries of mutated IL-2 displayed on the surface of yeast and isolated mutants with a 15-30-fold improved affinity for the IL-2Ralpha subunit. These mutants do not exhibit appreciably altered bioactivity at 0.5-5 pM in steady-state bioassays, concentrations well below the IL-2Ralpha equilibrium binding constant for both the mutant and wild-type IL-2. A mutant was serendipitously identified that exhibited somewhat improved potency, perhaps via altered endocytic trafficking mechanisms described previously.
Insights
Researchers engineered interleukin-2 (IL-2) mutants with higher affinity for IL-2Ralpha, aiming to improve cancer therapies. These enhanced IL-2 variants show potential for more effective T-cell stimulation in treating metastatic cancers.
Area of Science:
- Immunology
- Biotechnology
- Oncology
Background:
- Interleukin-2 (IL-2) is used to treat metastatic renal carcinoma and melanoma.
- Current IL-2 therapies face limitations due to a narrow therapeutic window, causing insufficient T-cell stimulation at low doses and excessive NK cell activation at high doses.
Purpose of the Study:
- To engineer IL-2 mutants with increased affinity for the IL-2 receptor alpha subunit (IL-2Ralpha).
- To develop IL-2 variants with enhanced biological potency for improved cancer immunotherapy.
Main Methods:
- Screening libraries of mutated IL-2 displayed on yeast.
- Isolation of IL-2 mutants with significantly improved binding affinity to IL-2Ralpha.
Main Results:
- Identified IL-2 mutants with a 15-30 fold increase in affinity for IL-2Ralpha.
- Mutants showed no significant change in bioactivity at low picomolar concentrations (0.5-5 pM).
- One mutant demonstrated slightly improved potency, possibly due to altered endocytic trafficking.
Conclusions:
- Increased IL-2 affinity for IL-2Ralpha is a viable strategy for developing more potent IL-2 variants.
- Engineered IL-2 mutants hold promise for overcoming limitations in current IL-2-based cancer immunotherapies.
- Further research into the mechanisms of enhanced IL-2 mutants could refine therapeutic applications.
More Related Videos
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
08:40An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions
Published on: March 14, 2016